APA (7th ed.) Citation

B, Y., R, A., SFA, M., AM, A., SJ, K., N, E. A., . . . M, Z. (2026). Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: A real-world propensity-score matched study. Journal of neurology, neurosurgery, and psychiatry, 97(5), 398. https://doi.org/10.1136/jnnp-2024-335704

Chicago Style (17th ed.) Citation

B, Yamout, et al. "Comparative Effectiveness of Natalizumab and Anti-CD20 Monoclonal Antibodies in Relapsing-remitting Multiple Sclerosis: A Real-world Propensity-score Matched Study." Journal of Neurology, Neurosurgery, and Psychiatry 97, no. 5 (2026): 398. https://doi.org/10.1136/jnnp-2024-335704.

MLA (9th ed.) Citation

B, Yamout, et al. "Comparative Effectiveness of Natalizumab and Anti-CD20 Monoclonal Antibodies in Relapsing-remitting Multiple Sclerosis: A Real-world Propensity-score Matched Study." Journal of Neurology, Neurosurgery, and Psychiatry, vol. 97, no. 5, 2026, p. 398, https://doi.org/10.1136/jnnp-2024-335704.